Genmab A/S (CPH:GMAB)

Iteris Statistics

Total Valuation

Genmab has a market cap or net worth of DKK 85.30 billion. The enterprise value is 64.03 billion.

Market Cap	85.30B
Enterprise Value	64.03B

Important Dates

The next estimated earnings date is Thursday, August 7, 2025.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Genmab has 61.50 million shares outstanding. The number of shares has decreased by -61.77% in one year.

Current Share Class	61.50M
Shares Outstanding	61.50M
Shares Change (YoY)	-61.77%
Shares Change (QoQ)	+587.81%
Owned by Insiders (%)	1.12%
Owned by Institutions (%)	51.33%
Float	60.81M

Valuation Ratios

The trailing PE ratio is 10.95 and the forward PE ratio is 13.80. Genmab's PEG ratio is 9.03.

PE Ratio	10.95
Forward PE	13.80
PS Ratio	3.83
PB Ratio	2.33
P/TBV Ratio	3.88
P/FCF Ratio	10.67
P/OCF Ratio	10.35
PEG Ratio	9.03

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.99, with an EV/FCF ratio of 8.01.

EV / Earnings	8.14
EV / Sales	2.87
EV / EBITDA	7.99
EV / EBIT	8.45
EV / FCF	8.01

Financial Position

The company has a current ratio of 5.34, with a Debt / Equity ratio of 0.03.

Current Ratio	5.34
Quick Ratio	5.32
Debt / Equity	0.03
Debt / EBITDA	0.12
Debt / FCF	0.12
Interest Coverage	59.70

Financial Efficiency

Return on equity (ROE) is 22.80% and return on invested capital (ROIC) is 13.34%.

Return on Equity (ROE)	22.80%
Return on Assets (ROA)	11.54%
Return on Invested Capital (ROIC)	13.34%
Return on Capital Employed (ROCE)	18.83%
Revenue Per Employee	8.45M
Profits Per Employee	2.98M
Employee Count	2,682
Asset Turnover	0.54
Inventory Turnover	11.54

Taxes

In the past 12 months, Genmab has paid 1.26 billion in taxes.

Income Tax	1.26B
Effective Tax Rate	13.85%

Stock Price Statistics

The stock price has decreased by -26.22% in the last 52 weeks. The beta is 0.80, so Genmab's price volatility has been lower than the market average.

Beta (5Y)	0.80
52-Week Price Change	-26.22%
50-Day Moving Average	1,397.55
200-Day Moving Average	1,445.93
Relative Strength Index (RSI)	50.43
Average Volume (20 Days)	98,325

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of DKK 22.30 billion and earned 7.86 billion in profits. Earnings per share was 126.72.

Revenue	22.30B
Gross Profit	21.21B
Operating Income	7.58B
Pretax Income	9.13B
Net Income	7.86B
EBITDA	7.90B
EBIT	7.58B
Earnings Per Share (EPS)	126.72

Balance Sheet

The company has 22.27 billion in cash and 986.95 million in debt, giving a net cash position of 21.28 billion or 345.97 per share.

Cash & Cash Equivalents	22.27B
Total Debt	986.95M
Net Cash	21.28B
Net Cash Per Share	345.97
Equity (Book Value)	36.55B
Book Value Per Share	577.05
Working Capital	22.64B

Cash Flow

In the last 12 months, operating cash flow was 8.24 billion and capital expenditures -242.21 million, giving a free cash flow of 8.00 billion.

Operating Cash Flow	8.24B
Capital Expenditures	-242.21M
Free Cash Flow	8.00B
FCF Per Share	130.04

Margins

Gross margin is 95.12%, with operating and profit margins of 33.97% and 35.27%.

Gross Margin	95.12%
Operating Margin	33.97%
Pretax Margin	40.94%
Profit Margin	35.27%
EBITDA Margin	35.43%
EBIT Margin	33.97%
FCF Margin	35.87%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	61.77%
Shareholder Yield	n/a
Earnings Yield	9.22%
FCF Yield	9.38%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 9.65 and a Piotroski F-Score of 5.

Altman Z-Score	9.65
Piotroski F-Score	5